Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt repayments

Daily Values

Growth Metrics

Mannkind (MNKD) Long-Term Debt Issuances (2010 - 2025)

Mannkind (MNKD) reported Long-Term Debt Issuances of $250.0 million for Q4 2025, up 8.7% on a QoQ basis from $230.0 million in Q1 2021.

Mannkind (MNKD) has 8 years of Long-Term Debt Issuances data on file, last reported at $250.0 million in Q4 2025.

Quarterly Long-Term Debt Issuances changed N/A year-over-year to $250.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $250.0 million (changed N/A YoY) and the FY2025 annual result came in at $325.0 million, changed N/A from the prior year.
Long-Term Debt Issuances grew to $250.0 million in Q4 2025 per MNKD's latest filing, from $230.0 million in the prior quarter.
Across five years, Long-Term Debt Issuances topped out at $250.0 million in Q4 2025 and bottomed at $230.0 million in Q1 2021.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Quantum Biopharma	961,148.99 Bn	961,148.98 Bn	-	2.73 Mn
2	Alterity Therapeutics	744,933.29 Bn	744,933.26 Bn	-	-
3	Legend Biotech	2,540.00 Bn	2,539.71 Bn	242.10 Mn	-
4	Nanobiotix	2,199.85 Bn	2,199.78 Bn	-	-
5	Akari Therapeutics	1,635.88 Bn	1,635.88 Bn	-	-
6	Vertex Pharmaceuticals	111.32 Bn	104.07 Bn	2.59 Bn	-
7	Evaxion A	62.56 Bn	62.54 Bn	-	-
8	Regeneron Pharmaceuticals	62.55 Bn	53.79 Bn	3.31 Bn	-
9	Alnylam Pharmaceuticals	39.57 Bn	36.56 Bn	959.66 Mn	-
10	Mannkind	1.09 Bn	956.66 Mn	82.66 Mn	-

Historic Data

Download Data 🔒

Date	Value
Dec 31, 2025	250.00 Mn
Dec 31, 2025	250.00 Mn
Mar 31, 2021	230.00 Mn
Mar 31, 2021	230.00 Mn
Jun 30, 2020	-27,000.00
Jun 30, 2020	-27,000.00
Dec 31, 2014	20.00 Mn
Dec 31, 2014	20.00 Mn
Dec 31, 2013	40.00 Mn
Dec 31, 2013	40.00 Mn
Dec 31, 2012	1.50 Mn
Dec 31, 2012	1.50 Mn
Sep 30, 2012	5.00 Mn
Sep 30, 2012	5.00 Mn
Mar 31, 2012	6.25 Mn
Mar 31, 2012	6.25 Mn
Sep 30, 2011	35.00 Mn
Sep 30, 2011	35.00 Mn
Dec 31, 2010	-8.79 Mn
Dec 31, 2010	-8.79 Mn
Sep 30, 2010	18.79 Mn
Sep 30, 2010	18.79 Mn